Procedures volumes have started picking up and pricing pushbacks from
payers has eased, leading many stocks in the orthopedics space to log
good runs. Smith & Nephew plc (NYSE: SNN ) has done better than peers/rivals like Stryker (NYSE: SYK ) and Zimmer
over the last twelve months, but oddly enough it may yet offer more
value. The company's knee business appears to be regaining some share
and the acquisition of Arthrocare (NASDAQ: ARTC ) should be a highly synergistic opportunity to grow in a space that offers better prospects than major joint reconstruction.
Continue here:
Could Smith & Nephew Plc Be a Good Value?
No comments:
Post a Comment